Charts

Cerus ( NASDAQ:CERS ) First Quarter 2024 Results Key Financial Results Revenue: US$38.4m (up 24% from 1Q 2023). Net...

Cerus Corporation (NASDAQ:CERS) Q1 2024 Earnings Call Transcript May 2, 2024 Cerus Corporation misses on earnings expectations. Reported EPS is $-0.0532 EPS, expectations were $-0.04. Cerus Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, ladies and gentlemen. […]

Q1 2024 Cerus Corp Earnings Call

Explore key financial outcomes and strategic insights from Cerus Corp's first quarter of 2024, reflecting robust product sales and operational advancements.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips CERS stock results show that Cerus met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. The post CERS Stock Earnings: Cerus Meets EPS, Misses Revenue for Q1 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

Key Financials and Developments in the First Quarter

Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2024.

Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

Key Insights Significantly high institutional ownership implies Cerus' stock price is sensitive to their trading...

U.S. stock futures were mixed this morning, with the Dow futures falling by around 10 points on Monday. Shares of Perion Network ...

Gainers Longeveron (NASDAQ:LGVN) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at ...

Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year. All INTERCEPT Platelet Processing Sets in both customer and Cerus inventories are now eligible for this six-month extension. This shelf-life extension applies to all sizes of INTERCEPT Platelet Processing Sets currently available in the U.S.

Investors eyeing a purchase of Cerus Corp. (CERS) shares, but tentative about paying the going market price of $1.93/share, might benefit from considering selling puts among the alternative strategies at their disposal..

On Wednesday, Cathie Wood-led Ark Invest made a significant move by offloading shares of Block Inc (NYSE:SQ) amidst Bitcoin (CRYPTO: ...

In trading on Wednesday, the iShares Latin America 40 ETF is outperforming other ETFs, up about 1.1% on the day. Components of that ETF showing particular strength include shares of NU Holdings, up about 1.9% and shares of Sociedad Quimica Y Mineral, up about 1.9% on the day.

Tuesday,Cerus Corporation(NASDAQ:CERS) announced topline results for the ReCePI Phase 3 trial of pathogen-reduced INTERCEPT ...

Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients. The trial met its primary efficacy endpoint, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs as measured by the incidence of acute kidney injury (AKI) following transfusion of study RBCs. AKI is a sensitive transfusion efficacy indicator of RBC tissue oxygen delivery. In transfused subjects, by modified intent to treat (mITT pre-specified primary endpoint population) the incidence of AKI was 29.3% (46/157) for INTERCEPT RBC recipients compared to 28.0% (45/161) for conventional RBC recipients, demonstrating non-inferiority of INTERCEPT RBCs compared to conventional RBCs with an upper limit of the 95% confidence interval of 10.4% compared with a non-inferiority margin of 14.0% (p = 0.001).

On March 14, 2024, William Greenman, President and Chief Executive Officer of Cerus Corp (NASDAQ:CERS), sold 125,926 shares of the company, according to a recent SEC Filing.

Cerus Corp (NASDAQ:CERS), a company specializing in the field of blood transfusion safety with its innovative INTERCEPT Blood System, has reported an insider transaction involving its Chief Operating Officer, Vivek Jayaraman.

On Wednesday, Cathie Wood-led Ark Invest made significant trades involving Coinbase Global Inc (NASDAQ:COIN) and Pinterest Inc ...

It's been a good week for Cerus Corporation ( NASDAQ:CERS ) shareholders, because the company has just released its...

Full-Year 2024 Revenue Guidance Reiterated Amidst Sequential Revenue Growth

Cerus Corporation (NASDAQ:CERS) Q4 2023 Earnings Call Transcript March 5, 2024 Cerus Corporation reports earnings inline with expectations. Reported EPS is $-0.01 EPS, expectations were $-0.01. Cerus Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day ladies and […]

Cerus ( NASDAQ:CERS ) Full Year 2023 Results Key Financial Results Revenue: US$156.4m (down 3.5% from FY 2022). Net...

Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter ...

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday. Shares of Box, Inc. (NYSE: BOX) rose ...

Q4 2023 Cerus Corp Earnings Call

InvestorPlace - Stock Market News, Stock Advice & Trading Tips CERS stock results show that Cerus beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. The post CERS Stock Earnings: Cerus Beats EPS, Misses Revenue for Q4 2023 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers NKGen Biotech (NASDAQ:NKGN) stock increased by 62.4% to $1.4 during Tuesday's after-market session. The company's market cap ...

Cerus (NASDAQ:CERS) reported its Q4 earnings results on Tuesday, March 5, 2024 at 04:00 PM. Here's what investors need to know about the ...

Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2023.

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of ...

Cerus (NASDAQ:CERS) is set to give its latest quarterly earnings report on Tuesday, 2024-03-05. Here's what investors need to know ...

In this article, we will take a detailed look at the 12 Best Rising Penny Stocks To Buy. For a quick overview of such stocks, read our article 5 Best Rising Penny Stocks To Buy. Stocks are roaring after Nvidia posted yet another strong quarter, crushing AI naysayers who were calling the stock overvalued and the AI wave a hype. […]

Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

U.S. stocks traded mostly higher, with the Dow Jones gaining around 70 points on Tuesday. Shares of GE HealthCare Technologies Inc. ...

Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares US.

The widely followed growth investor keeps making moves.

These innovation-oriented companies could take flight this year.

Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2023 and provided product revenue guidance for full-year 2024.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Health Care Equipment ETF (XHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $96.32 per unit.

Investors considering a purchase of Cerus Corp. (CERS) stock, but tentative about paying the going market price of $2.27/share, might benefit from considering selling puts among the alternative strategies at their disposal..

Gainers Celldex Therapeutics (NASDAQ:CLDX) stock increased by 30.1% to $33.8 during Monday's pre-market session. The company's market ...

Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023.

Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today announced that it has entered into an agreement with Cerus Corporation (NASDAQ: CERS) to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT® Fibrinogen Complex, or “IFC”) via the Bloodbuy online marketplace. Bloodbuy’s flagship cloud-based platform connects hospitals, blood centers, and life sciences organizations using its multi-patented B2B e-commerce and computer networking technologies for blood and biological products.

Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2023 financial results will be released on Thursday, November 2, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2023 AABB Annual Meeting, taking place in Nashville, TN from October 14 through October 17. This year’s AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies.

Cerus Corporation (Nasdaq: CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will focus on sustaining and evolving the talent and organizational structure to support the future of the business as the leader in safeguarding the global blood supply. Ms. Goodman will also serve as a member of the Company’s Executive Leadership Team.

Investors considering a purchase of Cerus Corp. (CERS) stock, but tentative about paying the going market price of $1.55/share, might benefit from considering selling puts among the alternative strategies at their disposal..

Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, at 10:30 a.m. EST.

In trading on Thursday, the Invesco China Technology ETF (CQQQ) is outperforming other ETFs, up about 3.6% on the day. Components of that ETF showing particular strength include shares of Dada Nexus (DADA), up about 8.4% and shares of Kingsoft Cloud Holdings (KC), up about 6.4% on the day.

Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2023.

Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2023 financial results will be released on Wednesday, August 2, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and a lunch symposium at the 33rd Regional International Society of Blood Transfusion (ISBT) Congress, taking place in Gothenburg, Sweden, from June 17 through June 21. Transfusion medicine experts and professionals from around the world attend the ISBT Congress. This year marks the first time the conference has taken place in person since 2019.

Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2023.

Cerus Corporation (Nasdaq: CERS) today announced that it has been awarded an additional $8.7 million contract amendment to the original $9.1 million contract by the U.S. Department of Defense (DoD) Industrial Base Analysis and Sustainment (IBAS) program for the development of pathogen reduced, lyophilized cryoprecipitate (“LyoCryo”) to treat bleeding due to trauma.

Cerus (NASDAQ:CERS) brought in sales totaling $30.97 million during Q1 according to data provided by Benzinga Pro. However, earnings ...

Cerus (NASDAQ:CERS) reported its Q1 earnings results on Thursday, May 4, 2023 at 04:00 PM. Here's what investors need to know about the ...

Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2023.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This year promises to be very different for Cathie Wood stocks, as signs of economic improvement become more prominent. The post 7 Best Cathie Wood Stocks for Your May 2023 Buy List appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Wall Street Titan: Here’s My #1 Stock for 2023 It doesn’t matter if you have $500 or $5 million. Do this now.

Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2023 financial results will be released on Thursday, May 4, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.